|Day Low/High||0.00 / 0.00|
|52 Wk Low/High||48.83 / 84.00|
Tech giants, Big Pharma and insurers are all angling to profit from the $3 trillion-plus U.S. healthcare market.
St. Jude Medical, Inc.
St. Jude shares deserve to be higher ahead of the merger with Abbott Labs. Here's why.
Political pressure is weighing on drug and medical device stocks including Abbott Labs and St. Jude, says Jim Cramer.
Miles White also reiterated that Abbott Laboratories has no plans to divest of its diabetes business. He still believes in Alere over the long term.
The medical device maker responded to allegations that its devices could be hacked during its third quarter earnings call.
St. Jude Medical (STJ) reported earnings that fell short of Wall Street's projections on Wednesday.
They plan to sell portions of their vascular closure and electrophysiology businesses to Japan's Terumo Corp. for $1.12 billion.
- The agreement is an important step toward completion of Abbott's acquisition of St. Jude Medical
Analysts are expecting St. Jude Medical's (STJ) 2016 third-quarter earnings and revenue to rise year-over-year.
St. Jude Medical, Inc.
Investors will get a slew of earnings reports from major companies and a host of Federal Reserve speakers during the week of Oct. 17.
Illumina fell 24% on news that it was cutting revenue guidance.
U.S. stocks bottom out during Tuesday afternoon's session as a disappointing quarterly performance from Alcoa heralds a poor start to the third-quarter earnings season.
St. Jude's (STJ) issue with batteries in its implanted heart devices is unlikely to spiral into a bigger problem, Cowen & Co. says.
On days like this, the money just keeps sloshing around.
Many investors were exiting their investments in the medical-device giant on news of the warning.
St. Jude's warning about battery risks in its implanted heart devices are big but will likely not disrupt its deal with Abbott Labs.
St. Jude Medical's defibrillators are having problems with batteries, but this likely won't affect Abbott Laboratories' acquisition of the medical device maker.
Abbott agreed to acquire St. Jude Medical for $25 billion, or about $85 per share. But with an alert on a major St. Jude product, what now? Cramer wonders.
Shares of Illumina were tanking before the opening bell after unveiling a disappointing sales forecast.
St. Jude (STJ) said that batteries within its implanted heart devices could unexpectedly deplete.